Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumacaftor/ivacaftor in cystic fibrosis with A455E-CFTR mutation
2016-001585-29Phase 2Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lumacaftor and ivacaftor in cystic fibrosis (CF) (2 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Absolute change from baseline in percent predicted forced expiratory volume in 1 second. Started Jul 2016; status: completed.
02
Drugs
lumacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2016-001585-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001585-29.